TAC-100 is under clinical development by Triumvira Immunologics and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TAC-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TAC-100 overview
TAC-01HER2 is under development for the treatment of HER2-positive solid tumors including breast cancer, pancreatic cancer, endometrial cancer, ovarian cancer, colorectal cancer, esophagus cancer, gastric cancer, gallbladder cancer and gastroesophageal (GE) junction carcinomas. It is administered by intravenous route. The drug candidate is developed based on TAC technology where T-cells are engineered to express T-cell Antigen Coupler (TAC) receptor. It acts by targeting cells expressing HER2 (human epidermal growth factor receptor) and cells expressing Claudin 18.2 (CLDN18.2). It was also under development for the treatment of glioblastoma multiforme, ovarian cancer, and sarcoma.
Triumvira Immunologics overview
Triumvira Immunologics (Triumvira) is a biopharmaceutical company that develops novel cancer therapies. The company uses chimeric antigen receptors and engineered T-cell receptors for the development of therapies. Triumvira is involved in the investigation of the mechanism in which TAC directs the engineered T-cells to target antigens and activates the T-cells after binding with antigen. The company’s product pipeline includes TAC01-HER2 and TAC02-HER2 for autologous and allogenic solid tumors which are in the initial stages of development. It operates a research facility in Hamilton, Ontario, Canada. Triumvira is headquartered in Austin, Texas, the US.
For a complete picture of TAC-100’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
